HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects

Catherine Butkus Small, David A Margolis, Mark S Shaefer, Lisa L Ross, Catherine Butkus Small, David A Margolis, Mark S Shaefer, Lisa L Ross

Abstract

Background: The presence of the HLA-B*57:01 allele in HIV-infected subjects is associated with a higher risk of abacavir-associated hypersensitivity reaction (ABC HSR). HLA-B*57:01 allele prevalence varies in different populations, but HLA-B*57:01 testing with immunological confirmation has had a negative predictive value for ABC HSR between 97 and 100%.

Methods: In the ASSURE study (EPZ113734), the HLA-B*57:01 prevalence in virologically suppressed, antiretroviral treatment-experienced, HIV-infected subjects from the United States, including Puerto Rico, was assessed.

Results: Three hundred eighty-five subjects were screened; 13 were HLA-B*57:01 positive and 372 were negative. Only HLA-B*57:01-negative, abacavir-naive subjects were eligible to enroll into the ASSURE trial. Eleven of the 13 subjects who possessed the HLA-B*57:01 allele were white, the other 2 were African-American. There was no geographic clustering of HLA-B*57:01-positive subjects, and the incidence correlated roughly with those states with the greatest numbers of subjects screened. Similarly, there was no statistically significant correlation between subjects who possessed or lacked the allele and age, gender, ethnicity or CD4+ T-cell numbers. The incidence of ABC HSR following abacavir initiation was also evaluated. Only 1 of 199 HLA-B*57:01-negative subjects (an African-American male) randomized to receive abacavir-containing treatment developed symptoms consistent with suspected ABC HSR; ABC HSR was not immunologically confirmed.

Conclusions: These findings confirm the utility of HLA-B*57:01 allele testing to reduce the frequency of ABC HSR. The prevalence of HLA-B*57:01 positivity was higher in white than in African-American subjects. In HLA-B*57:01-negative subjects, suspected ABC HSR is very rare, but should lead to discontinuation of abacavir when ABC HSR cannot be definitively excluded from the differential diagnosis.

Trial registration: The ASSURE (EPZ113734) study was registered on ClinicalTrials.gov registration on April 8th 2010 and the registration number is NCT01102972.

Keywords: Abacavir; HIV infection; HLA-B*57:01; Hypersensitivity; Lamivudine.

Figures

Fig. 1
Fig. 1
HLA-B*57:01 prevalence by state within the subject population at the screening visit

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 14 July 2016). . Accessed 15 Aug 2016.
    1. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321–333. doi: 10.1001/jama.2010.1004.
    1. European AIDS Clinical Society Guidelines Version 8.0., Updated June 2016. . Accessed 15 Aug 2016.
    1. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34:1137–1142. doi: 10.1086/339751.
    1. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579. doi: 10.1056/NEJMoa0706135.
    1. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–1118. doi: 10.1086/529382.
    1. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565–573. doi: 10.1016/S0149-2918(02)85132-3.
    1. Rodríguez-Nóvoa S, García-Gascó P, Blanco F, et al. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retrovir. 2007;23:1374–1376. doi: 10.1089/aid.2006.0244.
    1. Jesson J, Dahourou D, Renaud F, et al. Adverse events associated with abacavir use in HIV-infected children and adolescents: a systemic review and meta-analysis. Lancet HIV. 2016;3:e64–e75. doi: 10.1016/S2352-3018(15)00225-8.
    1. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732. doi: 10.1016/S0140-6736(02)07873-X.
    1. Squires KE, Young B, DeJesus E, et al. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010;11:69–79. doi: 10.1310/hct1102-69.
    1. TRIUMEQ (dolutegravir/abacavir/lamivudine) prescribing information. 2016. . Accessed 31 Jan 2017.
    1. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Ann Rev Genom Hum Genet. 2008;9:403–433. doi: 10.1146/annurev.genom.9.081307.164258.
    1. Cao K, Hollenbach J, Shi X, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009–1030. doi: 10.1016/S0198-8859(01)00298-1.
    1. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203–211. doi: 10.1517/phgs.5.2.203.27481.
    1. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther. 2003;8:36–41.
    1. Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One. 2014;9 doi: 10.1371/journal.pone.0096187.
    1. Norcross MA, Luoa S, Lua L, et al. Abacavir induces loading of novel self-peptides into HLA-BM57:01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26:F21–F29. doi: 10.1097/QAD.0b013e328355fe8f.
    1. Adam J, Eriksson KK, Schnyder B, et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 2012;42:1706–1716. doi: 10.1002/eji.201142159.
    1. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486:554–558.
    1. Illing P, Mifsud N, Purcell A. Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. Curr Opin Immunol. 2016;42:31–40. doi: 10.1016/j.coi.2016.05.003.
    1. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS. 2007;21:2533–2534. doi: 10.1097/QAD.0b013e328273bc07.
    1. Bonta PI, Vermeulen JN, Speelman P, Prins JM. Severe abacvir hypersensitivity reaction in a patient tested HLA-B*5701-negative. AIDS. 2008;22:1522–1523. doi: 10.1097/QAD.0b013e3283065ba1.
    1. Bennin CL. A rare case of abacavir hypersensitivity syndrome. Med Forum. 2010;12:37–38.
    1. Fox J, Newton P, Daly R, et al. An unusual abacavir reaction. AIDS. 2008;22:1520–1522. doi: 10.1097/QAD.0b013e328305bd9e.
    1. Calza L, Rosseti N, Biagetti C, et al. Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative. Int J STD AIDS. 2009;20:276–277. doi: 10.1258/ijsa.2008.008318.
    1. Esser S, Jablonka R, Heinemann FM, et al. Detection of abacavir hypersensitivity by ELISpot method. Inflamm Allergy Drug Targets. 2012;11:227–234. doi: 10.2174/187152812800392751.
    1. Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci. 2009;46:153–165. doi: 10.1080/10408360902937817.
    1. EPZICOM (abacavir/lamivudine) prescribing information. 2015. . Accessed 31 Jan 2017.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe